PRIMARY PAYER MARKET RESEARCH

The Formulary Insights Suite of Products Harvests Unbiased P&T Insights to Inform Access Strategies.

1. FIRST-CIRCLE.png

Premise

P&T drug evaluations have more influence on a product’s formulary status than all of its published clinical trials combined

Challenge

P&T drug evaluations are neither peer-reviewed nor public and exist as a crucial “blind spot” for manufacturers

Solution

The controlled completion of drug evaluations by active practitioners as a means to objectively assess and anticipate future P&T judgements on the clinical evidence.

Deliverables

- Analysis of monograph patterns (e.g. studies included and excluded, study grading)

- A composite drug or class monograph representing the payer perspective

4 direct inquiry.png

Premise

Precise payer insights can be solicited and delivered in rapid fashion to inform strategy decisions

Challenge

Current sources of payer insights require weeks or months to harness and lack relevance to today’s market

Solution

The rapid and customized inquiry of existing access decision makers in order to inform imminent strategy decisions

Deliverables

- Detailed, aggregated feedback of panelists on a range of specific questions (clinical or business)


- Multiple choice, preference, and open text answers

7.PNG

Premise

Payer evaluations of study designs and results can inform promotion strategies of existing studies and study design decisions for future studies

Challenge

Manufacturers invest millions of dollars into the completion of key clinical trials, yet their investment is too often marginalized by key formulary decision makers

Solution

The systematic and comprehensive review of selected clinical trials by formulary decision makers across the US

Deliverables

- Detailed, aggregated feedback on one or more selected clinical trials
 

- Summary recommendations for future study designs

6.PNG

Premise

Access decisions can hinge on a single differentiating attribute found in a drug’s prescribing instructions

Challenge

Manufacturers cannot reliably nor comprehensively assess P&T perceptions of drug label attributes

Solution

The controlled comparison of drug labels by formulary decision makers across the US

Deliverables

- Aggregated summary of perceptions to include rankings and ratings for each section of the designated products
 

- Cataloging of payer perceptions regarding statistical significance, clinical significance, and rationale statements